Home  |  Contact

Cellosaurus XMMME-001 (CVCL_F817)

[Text version]

Cell line name XMMME-001
Synonyms IND1
Accession CVCL_F817
Resource Identification Initiative To cite this cell line use: XMMME-001 (RRID:CVCL_F817)
Comments Group: Patented cell line.
Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8759.
Biotechnology: The monoclonal antibody produced by this hybridoma was conjugated to a ricin chain A to produce XomaZyme-Mel (XMMME-001-RTA) which was evaluated in several clinical trials for metastatic melanoma patients (DOI=10.3390/antib1010039).
Monoclonal antibody isotype: IgG2a.
Monoclonal antibody target: Human melanoma tumor specific HMW antigen.
Species of origin Mus musculus (Mouse) (NCBI Taxonomy: 10090)
Hierarchy Parent: CVCL_3411 (P3X63Ag8)
Category Hybridoma

Kernan N.A., Knowles R.W., Burns M.J., Broxmeyer H.E., Lu L., Lee H.M., Kawahata R.T., Scannon P.J., Dupont B.
Specific inhibition of in vitro lymphocyte transformation by an anti-pan T cell (gp67) ricin A chain immunotoxin.
J. Immunol. 133:137-146(1984)

Scannon P.J., Spitler L.E., Lee H.M., Kawahata R.T., Mischak R.P.
Human melanoma specific immunotoxins.
Patent number US4590071, 20-May-1986

Becker N., Benhar I.
Antibody-based immunotoxins for the treatment of cancer.
Antibodies 1:39-69(2012)

Cell line collections ATCC; HB-8759
Cell line databases/resources CLO; CLO_0009652
Encyclopedic resources Wikidata; Q54994849
Entry history
Entry creation11-Feb-2013
Last entry update23-Sep-2021
Version number5